If one has congestive heart Failure and is experiencing shift between afib, atrial flutter and sinus rhythm after discovery sick sinus syndrome and placement of a transcatheter pacemaker and resuming therapy with amiodarone what are the next possible therapies?

The strongest evidence points to catheter ablation as the next step, but the data is older and the benefit may not be as large as the headlines suggest.

The evidence for catheter ablation in patients with heart failure and atrial fibrillation comes from trials that are mostly a decade old. The CAMTAF trial (2014) randomized 50 patients and found that ablation improved left ventricular ejection fraction by about 9 percentage points compared to medical rate control, and cut BNP levels by more than half [1]. An earlier NEJM study (2004) reported a 21-point improvement in ejection fraction after ablation in a single-group design [2]. A 2019 meta-analysis of 18 trials (4,464 patients) found that ablation reduced all-cause mortality by about 31% compared to medical therapy, but the authors noted that this result was driven almost entirely by the CASTLE-AF trial [3]. When CASTLE-AF was removed, the mortality benefit was no longer statistically significant [3]. The same meta-analysis found that ablation reduced cardiovascular hospitalizations by about 44%, though with high heterogeneity across studies [3].

The key limitation is that none of these trials directly tested the specific scenario you describe: a patient with sick sinus syndrome, a pacemaker, and active amiodarone therapy. The pacemaker complicates rhythm control because the device may be pacing the ventricle during atrial arrhythmias, and amiodarone carries its own risks, including thyroid, lung, and liver toxicity, as well as a documented 10% risk of cardiovascular collapse when given intravenously in children with depressed cardiac function [4]. The evidence does not tell us whether adding ablation to amiodarone in a paced patient is better than optimizing rate control alone.

My call: catheter ablation is a reasonable next option, but the evidence for it in your specific situation is indirect and the benefit may be smaller than the trial averages suggest. The safest approach is to discuss with an electrophysiologist whether the pacemaker settings can be adjusted to minimize ventricular pacing during atrial arrhythmias, and whether amiodarone can be reduced or replaced before considering ablation. Confidence: moderate for the general benefit of ablation in heart failure with atrial fibrillation, low for its benefit in a paced patient on amiodarone.